Arcutis Shares Climb on Strong Product Revenue Estimates

Dow Jones

01-13

By Dean Seal

Shares of Arcutis Biotherapeutics jumped after the company offered fourth-quarter preliminary product revenue results that topped analyst expectations.

The stock was up 8% at $14.92 in premarket trading. Shares were trading at around $3.64 this time a year ago.

The commercial-stage biopharmaceutical company said on Sunday that it expects to post about $63 million in product revenue for the quarter of 2024, which would be up from $13.5 million in the same quarter a year ago and $44.8 million in the prior quarter. Analysts polled by FactSet had been projecting $57.8 million.

That would result in product revenue of about $160 million for the full year, up more than fivefold from the 2023 total, Arcutis said.

The company said revenue growth was driven by strong demand for its Zoryve skin treatment products.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

January 13, 2025 07:21 ET (12:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503030913"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503030913\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503030913?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503030913","market":"sg","top_or_hot":-1,"title":"Arcutis Shares Climb on Strong Product Revenue Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Arcutis Biotherapeutics jumped after the company offered fourth-quarter preliminary product revenue results that topped analyst expectations. \n</p>\n<p>\n  The stock was up 8% at $14.92 in premarket trading. Shares were trading at around $3.64 this time a year ago. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said on Sunday that it expects to post about $63 million in product revenue for the quarter of 2024, which would be up from $13.5 million in the same quarter a year ago and $44.8 million in the prior quarter. Analysts polled by FactSet had been projecting $57.8 million. \n</p>\n<p>\n  That would result in product revenue of about $160 million for the full year, up more than fivefold from the 2023 total, Arcutis said. \n</p>\n<p>\n  The company said revenue growth was driven by strong demand for its Zoryve skin treatment products. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2025 07:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcutis Shares Climb on Strong Product Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcutis Shares Climb on Strong Product Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-13 20:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Arcutis Biotherapeutics jumped after the company offered fourth-quarter preliminary product revenue results that topped analyst expectations. \n</p>\n<p>\n  The stock was up 8% at $14.92 in premarket trading. Shares were trading at around $3.64 this time a year ago. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company said on Sunday that it expects to post about $63 million in product revenue for the quarter of 2024, which would be up from $13.5 million in the same quarter a year ago and $44.8 million in the prior quarter. Analysts polled by FactSet had been projecting $57.8 million. \n</p>\n<p>\n  That would result in product revenue of about $160 million for the full year, up more than fivefold from the 2023 total, Arcutis said. \n</p>\n<p>\n  The company said revenue growth was driven by strong demand for its Zoryve skin treatment products. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2025 07:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503030913","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503030913","pubTimestamp":1736770860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Arcutis Biotherapeutics jumped after the company offered fourth-quarter preliminary product revenue results that topped analyst expectations.The stock was up 8% at $14.92 in premarket trading. Shares were trading at around $3.64 this time a year ago.The commercial-stage biopharmaceutical company said on Sunday that it expects to post about $63 million in product revenue for the quarter of 2024, which would be up from $13.5 million in the same quarter a year ago and $44.8 million in the prior quarter. Analysts polled by FactSet had been projecting $57.8 million.That would result in product revenue of about $160 million for the full year, up more than fivefold from the 2023 total, Arcutis said.The company said revenue growth was driven by strong demand for its Zoryve skin treatment products.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"Arcutis股价因强劲的产品收入预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Arcutis Biotherapeutics jumped after the company offered fourth-quarter preliminary product revenue results that topped analyst expectations. \n\n\n  The stock was up 8% at $14.92 in premarket trading. Shares were trading at around $3.64 this time a year ago. \n\n\n  The commercial-stage biopharmaceutical company said on Sunday that it expects to post about $63 million in product revenue for the quarter of 2024, which would be up from $13.5 million in the same quarter a year ago and $44.8 million in the prior quarter. Analysts polled by FactSet had been projecting $57.8 million. \n\n\n  That would result in product revenue of about $160 million for the full year, up more than fivefold from the 2023 total, Arcutis said. \n\n\n  The company said revenue growth was driven by strong demand for its Zoryve skin treatment products. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 07:21 ET (12:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}